Merck shows PD-1's promise in breast cancer with positive early results

Merck's ($MRK) pembrolizumab, sold as Keytruda, showed promising signs of efficacy in a particularly deadly brand of breast cancer, early data that could expand the use for a new class of treatments expected to take the market by storm. Merck's treatment, approved to treat melanoma, charted an overall response rate of 18.5% in a study on women with triple-negative breast cancer, an aggressive form of the disease with no approved targeted therapies. The results suggest a wider use for so-called checkpoint inhibitors, a class of treatments that help expose cancer cells to the immune system's natural defenses and have thus far demonstrated efficacy in skin, lung and other cancers. Bristol-Myers Squibb ($BMY), Roche ($RHHBY) and AstraZeneca ($AZN) are among the companies developing similar therapies. More

Suggested Articles

The culture change is part of an effort to stop the fear of failure from pushing GSK researchers to make conservative decisions. 

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.